Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors
Abstract
Recombinant adeno-associated viral (rAAV) vectors represent a novel class of biopharmaceutical drugs. The production of clinical-grade rAAV vectors for gene therapy would benefit from analytical methods that are able to monitor drug product quality with regard to homogeneity, purity, and manufacturing consistency. Here, we demonstrate the novel application of analytical ultracentrifugation (AUC) to characterize the homogeneity of preparations of rAAV vectors. We show that a single sedimentation velocity run of rAAV vectors detected and quantified a number of different viral species, such as vectors harboring an intact genome, lacking a vector genome (empty particles), and containing fragmented or incomplete vector genomes. This information is obtained by direct boundary modeling of the AUC data generated from refractometric or UV detection systems using the computer program SEDFIT. Using AUC, we show that multiple parameters contributed to vector quality, including the AAV genome form (i.e., self-complementary vs. single-stranded), vector genome size, and the production and purification methods. Hence, AUC is a critical tool for identifying optimal production and purification processes and for monitoring the physical attributes of rAAV vectors to ensure their quality.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
AUC distinguishes partially filled from empty and full capsids.
“AUC has two advantages for the quantification of the content ratio: it is highly repeatable, at only 2% CV, and distinguishes partially filled from empty and full capsids.”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [49]
AUC is highly repeatable at 2% CV.
“AUC has two advantages for the quantification of the content ratio: it is highly repeatable, at only 2% CV, and distinguishes partially filled from empty and full capsids.”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [49]
AUC is limited to purified samples without residual impurities or excipients and requires prior titration into the linear range 2 × 10^12-5 × 10^12 cp/mL.
“Sensitivity of the detectors and the risk of induced density gradients limit AUC to purified samples without residual impurities or excipients, and prior titration into the small linear range of the detector, 2 × 1012–5 × 1012 cp/mL, is needed.”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [49]
In a single experiment, AUC assesses presence of aggregates and quantifies relative content of empty, partially filled, and full capsids.
“In a single experiment, AUC assesses the presence of aggregates and quantifies the relative content of empty, partially filled, and full capsids.”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [49]
AUC requires large sample volumes (400-500 μL) at high concentrations around 2 × 10^12-5 × 10^12 vg/mL, representing significant loss of unrecoverable material during early production stages.
“In general, AUC requires large sample volumes, 400–500 μL, at high concentrations around 2 × 1012–5 × 1012 vg/mL, representing a significant loss of unrecoverable material during early production stages.”
From Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies (2021) · cites this paper as [49]
The citation lists haven’t been fetched yet
References 48 · Cited by 150
- Authors
- Burnham, B., Nass, S., Kong, E., Mattingly, M., Woodcock, D., Song, A., Wadsworth, S., Cheng, S. H., Scaria, A., & O'Riordan, C. R.
- Affiliations
- Sanofi (United States) (US)
- Gene Therapy, Genzyme, a Sanofi Company, Framingham, Massachusetts.
- ORCID
- Wadsworth, Samuel
- Venue
- Human Gene Therapy Methods
- Publisher
- SAGE Publications
- Published
- 2015-12
- Volume
- 26
- Issue
- 6
- Pages
- 228-242
- ISSN
- 1946-6536 (ISSN-L)
- 1946-6544
- OpenAlex
- W1795014780
- Cited by
- 150
- References
- 48
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 22 · 2023: 32 · 2022: 11 · 2021: 25 · 2020: 8 · 2019: 11 · 2018: 7 · 2017: 5 · 2016: 3
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Gene Therapy Methods (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus vectors, analytical ultracentrifugation, settling velocity, genome fragmentation, self-complementary AAV, drug quality, gene therapy vectors
- MeSH terms
- Dependovirus, Cell Line, Chromatography, Ion Exchange, Genetic Vectors, Humans, Plasmids, Transduction, Genetic, Ultracentrifugation, Virus Replication, Gene Expression, Genes, Reporter, Cell Culture Techniques, Transgenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review